Julian is a Sales Director for the Aviva Investors Offshore Liquidity funds focusing on the European market. He is responsible for raising the profile of Aviva Investors with institutional investors across Europe, building our external asset base and delivering investment solutions to meet investors’ specific objectives.
Experience and qualifications
Prior to joining Aviva Investors, Julian was Head of Corporate Business - UK & Ireland at Amundi. He worked closely with Institutional clients providing off balance sheet cash solutions for clients looking at short-term investments, mainly money market funds and segregated mandates.
Julian graduated from the University of West London with a BA (Hons) in Business and also holds the CISI - UK Financial Regulation.
Investment Director, Credit
Sales Director, Liquidity - UK Corporates
Head of UK Liquidity Portfolio Management
Senior Portfolio Manager
Head of Credit
Sales Director, Liquidity – Financial Institutions
Global Head of Liquidity Client Solutions
Head of Short Duration - Liquidity
Senior Credit Research Analyst, Global Sector Lead for Real Estate, Infrastructure & Structured Finance
You might also be interested in
Global equity income Q&A: Richard Saldanha on the outlook for dividends and growth
3 Aug 2022
The lead manager of our Global Equity Income strategy discusses risks and opportunities for income-seeking investors in a turbulent time for markets.
Long income, short ESG windows: Matching real estate long income and responsible investing timelines
2 Aug 2022
Luke Layfield looks at how real estate long income can help address clients’ ESG responsible investing objectives and how respective timelines for implementing change can be best aligned.
What does the data say? Are we close to 1970’s-style stagflation?
29 Jul 2022
In this month’s instalment of our visual series on topical themes, we look at whether the global economy is heading towards stagflation.
Multi-asset allocation views: Is this the end of the 60/40 strategy?
20 Jul 2022
Government bonds have not acted as safe haven assets recently. Sunil Krishnan explores whether this spells the end of the traditional 60/40 allocation in multi-asset portfolios.
Convertible bonds: Five questions with David Clott
19 Jul 2022
In the first of a new series, David Clott assesses the key recent developments in the convertible bond market and outlines why this could be an attractive entry point into the asset class with Rico Pedrett.
Bumpy ride set to continue for credit investors
18 Jul 2022
The co-managers of the Aviva Investors Strategic Bond strategy give their views on the outlook for credit markets following the worst first-half in at least 40 years.
The AIQ Podcast: Taking stock of nature risk
15 Jul 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
UK Equity Income: Five questions with Chris Murphy
15 Jul 2022
The manager of our UK Equity Income strategy explains why investors need to change their mindsets about what to pay for growth and cautions against buying yield for its own sake.
EMD: On the bread line
6 Jul 2022
Russia’s war in Ukraine has contributed to soaring food prices, supercharging global inflation. Poorer countries will likely be hardest hit, adding to the risk of social unrest. With public finances and incomes already under strain, emerging-market debt investors should be on high alert.
Is stagflation set to make an unwanted return?
1 Jul 2022
A growing chorus of experts are warning of the return of stagflation – periods of high inflation with low or negative economic growth.
Investing in a just transition to net zero: A Q&A with Nick Robins
30 Jun 2022
Reaching net zero by 2050 will require significant injections of capital. But it is also an opportunity to rethink social relationships, as Professor Nick Robins explains.
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
What does the data say? Biodiversity loss: From horror to hope
24 Jun 2022
In this month’s instalment of our visual series on topical themes, we explore the world of biodiversity.
ESG investing: Lasting lessons from Russia’s war on Ukraine
23 Jun 2022
Russia’s invasion of Ukraine has led to ESG receiving widespread flak. While much of the criticism is unjustified, the episode underlines how many issues related to ESG are complex and involve trade-offs. Investment approaches may need fine tuning, especially if the geopolitical landscape continues to change so rapidly.
Levelling up for a new social contract
21 Jun 2022
The global financial crisis of 2007 and the COVID-19 pandemic widened social inequalities, with vulnerable communities hit the hardest. Governments, investors and companies all have a duty to address the issue.
UK Equities: Five questions with Charlotte Meyrick and Trevor Green
14 Jun 2022
Charlotte Meyrick and Trevor Green explain why 2022 has all been about getting your sector calls right in UK equities.